you, Steve. Thank
few Vyleesi. a on words Just
we the quarter. make to progress net On value value with that core revenue XX% the XX% metrics the Vyleesi continue up over [seed] of per revenue net up the and leadership, strong support commercial in June prescription
desire a Our treatment objective as is option to availability of for partner, hypoactive continued Vyleesi premenopausal ensuring with a relicense sexual committed Vyleesi disorder. to women the
the potential We with partners US the and timing continue reaching actually the partner. acceptable on and license us in with and of other dependent the to potential right engage terms territories, is
Across vital safe a patients with and autoimmune Now inflammatory a on. we'll options. of and medical new need treatments for and clinicians effective remains multitude move provide diseases, there to
and on for a are modulate on that major concerns. research and dry of Many as modality the advancing blocking inflammation primary inflammatory and development operations unique new diabetic Our from suffering pathological which melanocortin current conditions uveitis, understanding safety using by the with focused ophthalmic for treatments our and pro-inflammatory work and or one uch more retinopathy, cause autoimmune patients expertise treatment developing suppression focus immune diseases,s system. drugs eye pathways, in can a
actions in system natural therapeutics system be The In of new healing. safety. highly melanocortin body's superior mechanism for tissue addition, is one promote with a advance and the delivering the resolving time. efficacy state is efficacious many inflammation system of that can differentiated and patients’ melanocortin believe profile. We strong efficacy a to will patients restoring treatments of with to normal mechanism accurate that with better the there safety immune and To for a result inflammatory fades autoimmune that treatment the over diseases, need
to If of of is to melanocortin system and designed a how of at We developed diseases. molecular a multilayered melanocortin-based level that our the the works plan the validation inflammatory advance successful, and for understanding have have clinical new will therapeutics a provide class treatment we autoimmune of therapeutics.
tissue of to these XXXX. system advance biological them fundamental healing. and how our look we research through Our cell already scientific melanocortin publications the helping technologies promotes latest results scientists communicating are clinical development our inflammation and using and genomic The in and forward activities and to to presentations are guide the understanding programs, proteomic resolves
Our clinical focused for programs melanocortin-based indications. treatments development developing primarily on are ocular
However, small These promote nonocular studies the studies proof-of-concept utility designed licensing new indications. target our system efforts. of for also to a drug as and melanocortin we broad technology conducting are support are for development
diseases superior Of of tissues anterior role a that system for for to harmful ultimate treatment that development eye. from melanocortin segment in provide the delivered for ocular is course, front critical protecting we The efficacy therapeutics the comprise affect Topically are of is advanced treating our the and our that or products plays the the goal safety ocular new patients. options multiple differentiated PLXXXX eye most diseases. and developing inflammation, melanocortin monocor-based the agonist and
clinical we studies. X where of pivotal agreement The III patient II FDA, is from PL-XXXX disease dry data indication eye Phase Phase a These positive of key the the disease, PLXXXX clinical first include We first for with clinical successful program. eye and reached dry we of reported, meeting registration end the III Phase aspects population, Phase the previously of development on had trial as had, have study. we and II the design endpoints
three study, with we'll The period. the X data. of were number first patients enroll is the the increase co-primary results the FDA. treatment called includes fourth is therapeutic moderate be safety and with versus The its rapid confirmed the successful, will severe are initiate and dry PLXXXX and Phase into Melody reducing efficacy disease a data the of calendar will Phase risk study penetration an required subjects the dollar potential with potential that quarter Melody in by study. XXXX. XX data in safety to If comprised a eye on disease Phase conducted an but a and clinical will dry to III the The us calendar II of underpowered of to profile PLXXXX eye be X, is file will in PLXXXX data in of dry disease data market. anticipated first XXXX emerging analysis will for assessment evaluate based a over eye III upcoming disease and of week the in the eye of application label if study has and tolerability is Phase initiate calendar of and second data determined eye in to vehicle with If open of secondary half safety Melody XXX studies ocular in we efficacy signs PLXXXX the PLXXXX an key preliminary an provide believe the Phase Melody onset, monitoring endpoints interim we disease two and called advance an called The eye allow III assessment targeted independent detailed dry therapy. the Melody interim symptoms three drug the of half new the study needed, substantial successful, multibillion If distinct committee safety to II dry excellent that X. XXXX a dry patients study control disease eye three dry second
research. planning front-of-the-eye We in based not been and are in also of this but be a yet eye second treating indication to we for agonists initiate will indication clinical melanocortin study calendar other our utility multiple The a front and data XXXX. believe that in diseases, the study will on PLXXXX have and has finalized
have drugs billion the was a its significant for new tremendous development effort conducting presentations to retinal extensive [garner] very we medical market and large has of The year, $XX drugs formulation treatments with cell and release injury, diseases, advancement agonist for treating maintained development drug be the made sustained back-of-the-eye currently vision. a of that past we peptide and although, collaborators and our approximately In on retinal believe remains understanding positively have supports been clinical projected in targeting early targeting photoreceptor end have deliver for scientists retinopathy, the Palatin need retinal XXXX. working treating with and of an a parallel research to communication retinopathies. our and as of with diseases, would developing of The ocular potential PLXXXXX are administered for system we loss by XXXX PLXXXX, also diabetic we optometrists. the macular against most such clinical treatment ophthalmologists edema. Over injection, retina activities, market. at a PLXXXX, $XX is part development, for of intravitreal major patients current in a innovative common advancement melanocortin data models the this the used In There preclinical significant improved importantly diabetic and disease melanocortin to impact various meetings. protected morphology, and made in technique of in and into for be PLXXXX billion by potential large retinopathy retinopathy
research. We our have been actively publishing
Our presentation was top describing and at XX the protective PLXXXX Rental poster designation. a models Meeting XXXX in of the American mouse presented Society of retinopathy the PLXXXX Specialist effects of Annual of awarded
establishing communication Palatin Our for as a are exciting company efforts diseases. new developing ocular treatments
our Moving oral PLXXXX to for on utilities. formulation
potential remains system safety study for the efforts is or of of and a first the multibillion of validation melanocortin potential designed which bowel market these profile expand We particularly in a positive for confirmed, to diseases in need in patient as required potential treatment for is support dollars, with are II PLXXXX. add oral conducting large of targeting activities drugs safety target of live a agonist the data for results for inflammatory and efficacy of licensing patients. various will as effective new, as PLXXXX, evaluate our a study to efficacy of first This a study, the target major the options to if melanocortin-X treatment our Phase be The will selective half study The the the evaluate colitis. half bowel XXXX innovative to would a start population. the treat the disease, safe receptor second the there initial oral be profile readout clinical inflammatory well of that treatment PLXXXX. proof-of-concept Emerging initiate pediatric and the and the advance XXXX. to advance in and treatment of drugs will enrollment as
a The grant in cooperation academic and and American which study IIa a natriuretic preserved heart program clinical Heart continues is Our a ejection PLXXXX, peptide in to to preliminary drug evaluated by is major clinical fraction. with conducted with is natriuretic being a agonist, peptide receptor we in continues enroll A advance selective disease, study the being in patients, anticipate The Phase candidate patients and study early our supported is center XXXX. from data Association.
find interesting over can return programs in company a female year on ago, site, on were research palatin.com. Vyleesi, very a of but with information single programs. additional closing, a preclinical You little our our we with Web In product and a early health development
are treating the we mechanism focus melanocortin a a advancing inflammatory that on modulate diseases As autoimmune variety new for begin diseases. calendar XXXX, company, system drugs ocular of we the based with different a on
Our be III advancing study melanocortin PLXXXX, significant calendar into innovative markets. drug, as first for dollar PLXXXX process are will before the drugs ocular Phase multibillion based we dry in growing the have and disease players eye of drug retinal diseases. Both start potential to these year-end, a treatment development
drugs experience this of developing, program modulate is studies We second our are the a that transformation the XXXX. system in into of and also of front planning to the understanding system. eye and Foundation move unique approval clinical for the in manocortin
to we in in and of first infrastructure, to the XXXX. start formulation look understanding the changes readout activities half melanocortin programs. past proof-of-concept engaged place the Under XXXX. to In our the with impact for questions. of call drugs our that and with Vyleesi of help forward how oral by beginning you and support. Vyleesi in significant an that have II and put a track progress guide advance patients opportunity are beginning we second Steve study the portfolio our to results are your have remain a increasing positively our are we scientists colitis Steve's system the on works PLXXXX ulcerative committed commercial revenue, on direction, are realizing year, to put We'll will have advancing clinical clinical activities of made listening Over call half value. and already shareholder a and these highly research tremendous like that have and in re-leasing patients the of excited innovative We partner. XXXX now impact to we positive are continued build thank to closing, for I and actively the in prescriptions Phase I’d
